Literature DB >> 29074211

Large Cell Neuroendocrine Lung Carcinoma Transformation as an Acquired Resistance Mechanism to Osimertinib.

Charles Ricordel1, Francesco Llamas-Gutierrez2, Dan Chiforeanu2, Hervé Lena3, Romain Corre3.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2017        PMID： 29074211     DOI： 10.1016/j.jtho.2017.07.019

Source DB:  PubMed          Journal:  J Thorac Oncol        ISSN： 1556-0864            Impact factor:   15.609


× No keyword cloud information.
  4 in total

1.  Targeting the EMT transcription factor TWIST1 overcomes resistance to EGFR inhibitors in EGFR-mutant non-small-cell lung cancer.

Authors:  Zachary A Yochum; Jessica Cades; Hailun Wang; Suman Chatterjee; Brian W Simons; James P O'Brien; Susheel K Khetarpal; Ghali Lemtiri-Chlieh; Kayla V Myers; Eric H-B Huang; Charles M Rudin; Phuoc T Tran; Timothy F Burns
Journal:  Oncogene       Date:  2018-08-31       Impact factor: 9.867

2.  Successful treatment with osimertinib and its subsequent resistance mechanism in a patient with non-small-cell lung cancer harboring acquired EGFR T790M mutation after recovery from AC0010-induced interstitial lung disease.

Authors:  Hanping Wang; Li Zhang; Xiaohua Shi; Xiaotong Zhang; Xiaoyan Si
Journal:  Onco Targets Ther       Date:  2019-07-10       Impact factor: 4.147

Review 3.  Understanding Lineage Plasticity as a Path to Targeted Therapy Failure in EGFR-Mutant Non-small Cell Lung Cancer.

Authors:  Tatiana Shaurova; Letian Zhang; David W Goodrich; Pamela A Hershberger
Journal:  Front Genet       Date:  2020-03-27       Impact factor: 4.599

4.  An EGFR T790M-mutated lung adenocarcinoma undergoing large-cell neuroendocrine carcinoma transformation after osimertinib therapy: a case report.

Authors:  Shinichi Miyazaki; Yasumasa Kuno; Shunsaku Hayai; Ryo Teramachi; Ryo Yamashita; Yusuke Saito; Kosuke Higuchi; Yoshiharu Nara; Takuya Ikeda
Journal:  J Med Case Rep       Date:  2020-08-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.